An interventional study of Stereoscopic (3D) Movie Viewing and 2D Movie Viewing in Amblyopia and Strabismus, sponsored by Universitat Politècnica de Catalunya. Not yet recruiting. Open to participants aged 4 Years to 14 Years. Per ClinicalTrials.gov, last updated 2025-12-24.
Sponsored by Universitat Politècnica de Catalunya · Not applicable, Interventional, and Treatment
This clinical study investigates whether watching 3D films can help improve the vision of children with residual amblyopia (lazy eye), that is, those children who, despite having undergone usual treatments such as glasses or patching, still maintain some visual deficit. The main objective is to verify whether viewing in 3D is better than viewing in 2D in improving depth vision (stereopsis), visual acuity and ocular alignment. The hypothesis is that 3D films, by providing richer binocular stimuli, will produce greater improvements than the same 2D films.
Children between 4 and 14 years of age with residual, stable and previously treated unilateral amblyopia will be included. Participants will be recruited from the pediatric ophthalmology/optometry clinics of the Mútua University Hospital
The study will be conducted in two locations: the visual examinations will be performed at the Mútua University Hospital in Terrassa, and the film sessions at the Faculty of Optics and Optometry of Terrassa (FOOT, UPC), in rooms prepared with a projector and 3D glasses.
The design is randomized and controlled. In a first phase, the children will be randomly divided into two groups: one group will watch 3 films in 3D and the other will watch the same films in 2D. Then, in a second phase, all participants will watch 3 additional sessions in 3D. Four evaluation visits will be made: before starting, after phase 1, after phase 2 and a follow-up two months later. These visits will measure stereopsis, visual acuity, and ocular deviation with standard optometric tests.
Watching 3D movies is a safe and non-invasive activity; therefore, no significant risks are expected beyond some possible mild and transient discomfort such as eye strain or headache, which will be recorded if it occurs. Potential benefits include improved depth perception and other visual functions, and the results could open the door to new, fun and motivating therapeutic options for other children with amblyopia in the future.
189 studies on the registry are indexed under Amblyopia; 41 are open to participants now.
This study's planned enrollment of 40 is below the median of 60 across 137 interventional studies indexed under Amblyopia.
Browse Amblyopia studies →Universitat Politècnica de Catalunya is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Behavioral: Stereoscopic (3D) Movie Viewing
Behavioral: 2D Movie Viewing
Repeated binocular visual stimulation. Participants view age-appropriate commercial films under standardized conditions once a week for three consecutive weeks in Phase 1. In the experimental intervention, the films are viewed in stereoscopic 3D using active shutter glasses and a calibrated 3D projection system. Each session lasts 90-120 minutes. After Phase 1, all participants receive three additional weekly 3D sessions (delayed treatment extension).
Repeated binocular visual stimulation. Participants view age-appropriate commercial films under standardized conditions once a week for three consecutive weeks in Phase 1. In the control intervention, the films are viewed in 2D with identical duration and setting. Each session lasts 90-120 minutes. After Phase 1, all participants receive three additional weekly 3D sessions (delayed treatment extension).
Change from baseline in stereoacuity measured with the Random Dot 2 Stereo Test (log arcsec)
Stereoacuity will be assessed using the validated Random Dot 2 Stereo Test. Results will be recorded in arcseconds and analyzed as log arcsec. The primary endpoint is the change from baseline (T0) to each post-intervention assessment (T1 and T2) and follow-up (T3).
Time frame: Baseline (T0, Week 0), post-Phase 1 (T1, Week 3), post-Phase 2 (T2, Week 6), and follow-up (T3, 2 months after Phase 2)
Change from baseline in best-corrected visual acuity (BCVA) of the amblyopic eye measured with ETDRS (logMAR)
Best-corrected visual acuity of the amblyopic eye will be assessed using standardized ETDRS optotypes with the participant wearing habitual optical correction. Visual acuity will be recorded in logMAR. The outcome is the change in BCVA from baseline (T0) to each post-intervention assessment (T1 and T2) and follow-up (T3).
Time frame: Baseline (T0, Week 0), post-Phase 1 (T1, Week 3), post-Phase 2 (T2, Week 6), and follow-up (T3, 2 months after Phase 2).
Change from baseline in ocular deviation measured by cover test with prism bars at distance (6 m) and near (40 cm) (prism diopters)
Ocular deviation will be assessed using the cover test with prism bars at distance (6 m) and near (40 cm). The magnitude and direction of deviation will be recorded in prism diopters (PD/DP), distinguishing esotropia and exotropia when present. The outcome is the change in ocular deviation from baseline (T0) to each post-intervention assessment (T1 and T2) and follow-up (T3).
Time frame: Baseline (T0, Week 0), post-Phase 1 (T1, Week 3), post-Phase 2 (T2, Week 6), and follow-up (T3, 2 months after Phase 2)
Change from baseline in binocular sensory status (suppression/fusion) measured by the Worth 4 Dot test at distance and near.
Binocular sensory status will be assessed using the Worth 4 Dot test at distance and near. Participants will be classified as showing fusion or suppression (and, if applicable, diplopia) based on standard Worth 4 Dot criteria. The outcome is the change in binocular sensory status from baseline (T0) to post-intervention assessments (T1 and T2) and follow-up (T3).
Time frame: Baseline (T0, Week 0), post-Phase 1 (T1, Week 3), post-Phase 2 (T2, Week 6), and follow-up (T3, 2 months after Phase 2).
Retinal correspondence status assessed by the Bagolini striated lens test
Retinal correspondence will be evaluated using the Bagolini striated lens test under standard clinical conditions. Participants will be classified as showing normal retinal correspondence, anomalous retinal correspondence, or suppression according to Bagolini response patterns. Results will be reported at each assessment time point.
Time frame: Baseline (T0, Week 0), post-Phase 1 (T1, Week 3), post-Phase 2 (T2, Week 6), and follow-up (T3, 2 months after Phase 2)
Vision-related quality of life measured by the Pediatric Eye Questionnaire (PedEyeQ) total score
Vision-related quality of life will be assessed using the age-appropriate PedEyeQ modules (child self-report and/or parent-proxy, plus parent component). Total PedEyeQ scores will be calculated according to the scoring manual and reported at each assessment time point.
Time frame: Baseline (T0, Week 0), post-Phase 1 (T1, Week 3), post-Phase 2 (T2, Week 6).
Participant/family satisfaction with the intervention measured by a study-specific Likert satisfaction questionnaire
Participant/family satisfaction will be measured using a structured study-specific questionnaire with Likert-type items (e.g., enjoyment, comfort, perceived benefit, and willingness to repeat). Satisfaction scores will be summarized and reported by group at each post-intervention time point.
Time frame: Post-Phase 1 (T1, Week 3), post-Phase 2 (T2, Week 6).
No study locations are listed for this record.
Plan to share: No
Start is estimated for Jan 2026; primary completion for Jul 2026, 6 months later.
Of 58 non-industry interventional studies with no phase under Amblyopia, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 72. This study's planned 6 months is below that.
Counting every sponsor, half of 71 studies reached it within 33 months; a quarter within 17 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitat Politècnica de Catalunya